Graham Capital Management, L.P. Zentalis Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $3.11 Billion
- Q2 2024
A detailed history of Graham Capital Management, L.P. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 11,465 shares of ZNTL stock, worth $37,031. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,465Holding current value
$37,031% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$45.1 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$27.6 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$15.6 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$14.5 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $184M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...